Results 1 to 10 of about 192 (165)
Сardioprotective agents with biaromatic structure. Part 6. Beta blockers
Фармакокинетика и Фармакодинамика, 2023 β-Blockers are one of the oldest classes of cardioprotectors used in the treatment of cardiovascular diseases. They reduce the heart rate, have a hypotensive effect, inhibit myocardial contractility and have antiarrhythmic properties.
G. V. Mokrov
doaj +4 more sources
Histochemical evaluation of T-2 toxin-induced cardiotoxicity in rats: Semiquantitative analysis [PDF]
Zbornik Matice Srpske za Prirodne Nauke, 2009 In this study female Wistar rats were treated with T-2 toxin (1 LD50 0.23 mg/kg sc) and sacrificed on days 1, 3, 5, 7, 14, 21, 28 and 60 after the treatment. Control groups of rats were treated by saline (1 ml/kg 0.9% NaCl).
Jaćević Vesna M. +6 more
doaj +3 more sources
Regulatory Mechanisms in Biosystems, 2016 Coronary heart disease is one of the major causes of illness and of deaths in Europe, therefore the definition of the signaling pathways involved in cardioprotection represents a challenging goal in order to discover novel pharmacological approaches. One
V. Paronik +3 more
doaj +3 more sources
Thioredoxin-1: a cardioprotector against stress [PDF]
Cardiovascular Research, 2020 This editorial refers to ‘Thioredoxin-1 maintains mitochondrial function via mTOR signaling in the heart’ by S.I. Oka et al., pp. 1742–1755.
Perone F., Lembo G.
openaire +3 more sources
Сardioprotective agents with biaromatic structure. Part 1. Calcium channel blockers
Фармакокинетика и Фармакодинамика, 2022 Cardiovascular diseases (CVD) are widespread and the leading cause of morbidity and mortality worldwide. Drugs for the treatment of CVD have been developed since the beginning of the 20th century.
G. V. Mokrov
doaj +1 more source
Сardioprotective agents with biaromatic structure. Part 3. Sodium channel blockers
Фармакокинетика и Фармакодинамика, 2022 This review continues a series of reviews on the analysis of compounds with cardioprotective properties in a number of biaromatic structures, which include a range of sodium channel blockers. Among voltage-gated sodium channels, the Nav1.5 isoform is the
G. V. Mokrov
doaj +1 more source
Сardioprotective agents with biaromatic structure. Part 2. HCN channel blockers
Фармакокинетика и Фармакодинамика, 2022 Hyperpolarization-activated cyclic nucleotide–gated (HCN) channels, primarily their HCN4 subtype, are one of the promising targets for the development of cardioprotective agents.
G. V. Mokrov
doaj +1 more source
Фармакокинетика и Фармакодинамика, 2023 The hERG subtype potassium channel (Kv11.1) is one of the most important and one of the most studied biological targets for the creation of cardioprotective agents.
G. V. Mokrov
doaj +1 more source
Сardioprotective agents with biaromatic structure. Part 5. Potassium Kv1.5-channels blockers
Фармакокинетика и Фармакодинамика, 2023 The Kv1.5 potassium channel provides an ultra-rapid delayed rectifier potassium current, IKur, that acts selectively in human atrial cells. This makes selective Kv1.5 blockade a promising approach to control atrial arrhythmias without the adverse ...
G. V. Mokrov
doaj +1 more source
Фармакокинетика и Фармакодинамика, 2023 The antiarrhythmic activity of bis-alkoxyphenyltriazaalkanes 1 and bis-alkoxyphenyldiazaalkanes 2 was analyzed in a model of reperfusion arrhythmia in rats.
V. V. Barchukov +7 more
doaj +1 more source